Combination phentermine/topiramate for obesity treatment in primary care: a review.

about

Fatty liver disease in diabetes mellitus Combination phentermine and topiramate extended release in the management of obesity.Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.

P2860

Q26996360-1A40D28F-3DA7-481C-8CCD-478CD51F4402 Q38469824-35791E82-1513-4995-B08C-BB2A2D52D0B6 Q38758765-0B1E7513-AB95-4288-A2AE-CC3642B02FBA

P2860

Combination phentermine/topiramate for obesity treatment in primary care: a review.

Item

http://www.wikidata.org/entity/Q38200830

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Combination phentermine/topiramate for obesity treatment in primary care: a review.

@en

type

Item

label

Combination phentermine/topiramate for obesity treatment in primary care: a review.

@en

prefLabel

Combination phentermine/topiramate for obesity treatment in primary care: a review.

@en

P1476

Combination phentermine/topiramate for obesity treatment in primary care: a review.

@en

P2093

Glen L Xiong

http://www.w3.org/2001/XMLSchema#string

Kishore M Gadde

http://www.w3.org/2001/XMLSchema#string

P2860

The PHQ-9: validity of a brief depression severity measure

Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial.

Influence of topiramate in the regulation of energy balance.

Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials.

Topiramate-induced weight loss: a review.

Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review.

Outpatient management of obesity: a primary care perspective.

Appetite suppressants. A review.

Screening for obesity in adults: recommendations and rationale.

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

P304

110-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3810/PGM.2014.03.2746

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24685974

http://www.w3.org/2001/XMLSchema#string

P921

Adipositas

Combination phentermine/topiramate for obesity treatment in primary care: a review.

about

P2860

P2860

Combination phentermine/topiramate for obesity treatment in primary care: a review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921